Medline vs Solventum
MDLN and SOLV side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MDLN and SOLV compare
Medline is the larger company, worth 3.5 times as much as Solventum ($52.6B against $15.1B).
Solventum scores higher on the StockData Score (6 against 2 for Medline), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MDLN | SOLV |
|---|---|---|
| Size and price | ||
| Market cap | $52.6B | $15.1B |
| Share price | $39.98 | $88.81 |
| Change, 1 year | – | 20.2% |
| Beta (5Y) | – | 0.51 |
| Employees | 45K | 10K |
| StockData Score | ||
| Total score | 2 | 6 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 99.8× |
| P/S | 1.7× (better) | 1.9× |
| P/B | 4.5× | 3.1× (better) |
| EV/EBITDA | 24.9× | 20.2× (better) |
| P/FCF | 27.7× | – |
| PEG | – | 22.14 |
| FCF yield | 3.6% (better) | 0.00% |
| Fair value | $23.69 | $45.74 |
| Margin of safety | −68.8% (better) | −94.2% |
| Growth | ||
| Revenue growth (TTM) | – | −2.8% |
| Net income growth (TTM) | – | −89.8% |
| EPS growth (TTM) | – | −89.8% |
| Profitability | ||
| Gross margin | 25.7% | 54.8% (better) |
| Operating margin | 5.7% (better) | 5.6% |
| Net margin | – | 1.9% |
| FCF margin | 6.2% (better) | 0.00% |
| Return on equity | – | 3.2% |
| Return on invested capital | 6.6% (better) | 4.7% |
| Financial health | ||
| Debt / equity | 1.07 | 1.05 (better) |
| Net debt / EBITDA | 3.24 (better) | 4.74 |
| Interest coverage | 2.5× | – |
| Current ratio | 4.04 (better) | 1.03 |
| Altman Z-score | 2.72 (better) | 1.85 |
| Piotroski F-score | – | 5 |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 57.1% | 75.0% |
| Held by insiders | 81.6% | 30.3% |
| Insider net buying, 12 months | −$14.3B | $100K (better) |
| Superinvestors holding | 4 (better) | 2 |
| Short interest, % of float | 15.7% | 4.3% |
Go deeper
- MDLN stock overview
- MDLN income statement
- MDLN valuation and score
- SOLV stock overview
- SOLV income statement
- SOLV valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.